Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market - GBI Research Reports

Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market

Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market - GBI Research Reports
Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market
Published Sep 01, 2011
142 pages — Published Sep 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market, which provides insights regarding therapeutic proteins sales forecasts until 2017. Therapeutic proteins markets in the key geographies of the US, the top five EU countries, and Japan are also covered in the report. The report also includes details about therapeutic proteins R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of the main therapeutic protein classes, which includes monoclonal antibodies, insulins, interferons, growth hormones, colony stimulating factors, erythropoietins and blood factors. Furthermore, it includes market forecasts for each therapeutic class. The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.

GBI Researchs analysis estimated the global therapeutic proteins market to be valued at $93billion in 2010, with a compound annual growth rate (CAGR) of 16.4% between 2002 and 2010. The market is forecast to grow at a CAGR of 6.2% between 2010 and 2017, to reach $141.5 billion in 2017. In-depth analysis in the report is based on proprietary databases, primary and secondary research, and in-house analysis by the GBI Research team of experts.

GBI Researchs analysis found the R&D pipeline for the therapeutic proteins market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that therapeutic proteins R&D activity will remain active for at least the next four to five years.

Scope

- The report analyzes market characterization, pipeline analysis and the competitive landscape in the therapeutic proteins market.
- Data and analysis of the therapeutic proteins market in the leading geographies of the world: the US, Europe and Rest of the World.
- Annualized market data for the therapeutic proteins market from 2002 to 2010, with forecasts to 2017 for blood factors, colony stimulating factors, erythropoietins, human growth hormone, insulin, interferons and monoclonal antibodies.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes.
- Key drivers and restraints that have had a significant impact on the market.
- Competitive landscape of the global therapeutic proteins market, including benchmarking of the top companies. The key companies studied in this report are Pfizer, Merck/Schering-Plough, F. Hoffmann-La Roche, Eli Lilly, Sanofi, Johnson and Johnson, Novo Nordisk, Amgen, Biogen and Abbott.

Reasons to buy

The report will aid business development and help marketing executives strategizing product launches -
- Build effective strategies to launch pipeline products, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of the top competitors.
- Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

  
Source:
Document ID
GBIHC080MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents38
  List of Tables63
  List of Figures92
Therapeutic Proteins Market: Introduction111
  GBI Research Report Guidance111
Therapeutic Proteins Market: Market Overview122
  Introduction121
    Drivers and Barriers121
      Drivers for the Therapeutic Proteins Market131
      Barriers for the Therapeutic Proteins Market131
Therapeutic Proteins Market: Market Characterization141
  Market Size141
Therapeutic Proteins Market: Geographical Landscape153
  Revenue Analysis by Geography151
  The US151
    Market Size151
  Europe161
    Market Size161
  ROW (Rest of the World)171
    Market Size171
Therapeutic Proteins Market: Therapeutic Landscape1842
  Introduction181
  Erythropoietins Market181
    Introduction181
    Market Size191
      The US Market201
      Europe211
      ROW221
    Annual Cost of Treatment for Major Therapies231
  Blood Factors Market241
    Introduction241
    Market Size251
      The US261
      Europe271
      ROW281
    Annual Cost of Treatment for Major Therapies291
  Interferons Market301
    Introduction301
    Market Size311
      The US321
      Europe331
      ROW341
    Annual Cost of Treatment for Major Therapies351
  Monoclonal Antibodies Market361
    Introduction361
    Market Size371
      The US381
      Europe391
      ROW401
    Annual Cost of Treatment for Major Therapies411
  Growth Hormones Market421
    Introduction421
    Market Size431
      The US441
      Europe451
      ROW461
    Annual Cost of Treatment for Major Therapies471
  Insulin Market481
    Introduction481
    Market Size491
      The US501
      Europe511
      ROW521
    Annual Cost of Treatment for Major Therapies531
  Colony Stimulating Factors Market541
    Introduction541
    Market Size551
      The US561
      Europe571
      ROW581
    Annual Cost of Treatment for Major Therapies591
Therapeutic Proteins Market: Pipeline Analysis609
  Introduction601
  Profiles of Promising Proteins in the Therapeutic Proteins Market601
    rhGAD65 (Diamyd)601
      Overview601
      Efficacy601
      Safety601
      Clinical Study Details601
    DiaPep277601
      Overview601
      Efficacy611
      Safety611
      Clinical Study Details611
    Otelixizumab611
      Overview611
      Efficacy611
      Safety611
      Clinical Trial Data611
    Oral-Lyn621
      Overview621
      Efficacy621
      Safety621
      Clinical Trial Data621
    NecLip-pdFVIII621
      Overview621
      Efficacy631
      Safety631
      Clinical Trial Study Details631
    OBI-1631
      Overview631
      Efficacy631
      Safety631
      Clinical Trial Data641
    NN7008641
      Overview641
      Efficacy641
      Safety641
      Clinical Trial Data641
    Long Acting rFactor VIII651
      Overview651
      Efficacy651
      Safety651
      Clinical Trial Data651
    Human-cl rhFVIII661
      Overview661
      Efficacy661
      Safety661
      Clinical Trial Data661
    Abthrax (raxibacumab)671
      Overview671
      Efficacy671
      Safety671
      Clinical Trial Data671
    Simponi (golimumab)681
      Overview681
      Efficacy681
      Safety681
      Clinical Trial Data681
Therapeutic Proteins Market: Competitive Landscape6952
  Evolving Competitive Landscape691
  Market Share Analysis691
    Major Companies691
  Competitive Profiling701
    Pfizer701
      Company Overview709
    Johnson &Johnson791
      Company Overview794
    Hoffmann-La Roche Ltd.831
      Company Overview834
    Merck &Co., Inc871
      Company Overview879
    Eli Lilly and Company961
      Company Overview968
    Abbott Laboratories1041
      Company Overview1044
    Sanofi1081
      Company Overview1086
    Novo Nordisk1141
      Company Overview1143
    Amgen1171
      Company Overview1172
    Biogen1191
      Company Overview1192
Therapeutic Proteins Market Strategic Consolidations12116
  Therapeutic Proteins Market Mergers and Acquisitions1211
    M&A Deals by Year1211
    M&A Deals by Value1221
    M&A Deals by Drug Class1221
    M&A Deals by Geography1231
    Major M&A Deals1241
      Pfizer Completes Acquisition of Wyeth1241
      Merck &Co Completes Merger with Schering-Plough1241
      Takeda Acquires Millennium Pharmaceuticals1251
      Eli Lilly Acquires ImClone Systems1251
      Teva Pharmaceutical Industries Completes Acquisition of ratiopharm1251
  Global Therapeutic Proteins Market Licensing Deals1261
    Licensing Deals by Year1261
    Licensing Deals by Value1271
    Licensing Deals by Drug Class1281
    Licensing Deals by Geography1291
    Major Licensing Deals1291
      Bristol-Myers Squibb Enters Into a Collaboration With ZymoGenetics1291
      Amgen Enters Into Licensing Agreement With Kyowa Hakko Kirin1301
      Lpath Enters Into Licensing Agreement With Pfizer1301
      Micromet Enters Into Licensing Agreement With Sanofi-Aventis1301
      Exelixis Enters Into Licensing Agreement With Bristol-Myers Squibb for XL4751311
  Global Therapeutic Proteins Market Co-Development Deals1321
    Co-Development Deals by Year1321
    Co-Development Deals by Value1331
    Co-Development Deals by Drug Class1331
    Co-Development Deals by Geography1341
    Major Co-Development Deals1341
      Eli Lilly Enters Into Co-Development Agreement with Boehringer Ingelheim1351
      GlaxoSmithKline Enters Into Co-Development Agreement With Chroma Therapeutics1351
      Wyeth Pharmaceuticals Enters Into Co-Development Agreement With Catalyst Biosciences1351
      Galapagos Expands Co-Development Agreement With Merck &Co.1361
      Galapagos Enters Into an Agreement With Merck1361
Global Therapeutic Proteins Market: Appendix1376
  Market Definitions1371
  Abbreviations1371
  Research Methodology1372
    Coverage1371
    Secondary Research1381
    Primary Research1381
  Therapeutic Landscape1392
    Epidemiology-based Forecasting1391
    Market Size by Geography1401
  Geographical Landscape1411
  Pipeline Analysis1411
  Competitive Landscape1411
    Expert Panel Validation1411
  Contact Us1411
  Disclaimer1411
  Sources1421

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market" Sep 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Therapeutic-Proteins-Market-to-2017-High-Demand-for-Monoclonal-Antibodies-will-Drive-the-Market-2115-242>
  
APA:
GBI Research Reports. (2011). Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market Sep 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Therapeutic-Proteins-Market-to-2017-High-Demand-for-Monoclonal-Antibodies-will-Drive-the-Market-2115-242>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.